Publications by authors named "Maria Esperanza Lopez Rubio"

Key Points: Kidney survival in C3 glomerulopathy is significantly higher in patients with a disease chronicity score <4 and proteinuria <3.5 g/d, regardless of baseline eGFR. A faster eGFR decline in C3 glomerulopathy is associated with higher probability of kidney failure.

View Article and Find Full Text PDF
Article Synopsis
  • C3 glomerulopathy is a rare kidney disease that affects how the complement system works, making it hard to predict individual patient outcomes.
  • Researchers conducted a study involving 115 patients across 35 nephrology centers to develop a nomogram that forecasts long-term kidney survival using factors like estimated glomerular filtration rate (eGFR), proteinuria, and chronicity score from kidney biopsies.
  • The final nomogram showed high accuracy (C-index of 0.860) in predicting kidney failure risk at 1, 2, 5, and 10 years, demonstrating reliable calibration between predicted and actual outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • C3 glomerulopathy associated with monoclonal gammopathy (C3G-MIg) is a rare kidney condition, and this study examined the clinical and histological characteristics of patients diagnosed with it between 1995 and 2021.
  • The study involved 23 patients, with a median age of 63 years, and found that a significant number reached kidney failure (39%) during an average follow-up of 40 months, with transplant recipients faring particularly poorly.
  • The researchers concluded that the C3G histologic index is useful for predicting kidney prognosis, noting that clone-targeted therapies improved survival rates in patients who responded to treatment.
View Article and Find Full Text PDF

Introduction: Previous reports have shown very high mortality among hemodialyisis patients. Our goal was to analyze the mortality of patients in the Renal Registry of Patients who remained exclusively on hemodialysis treatment.

Methods: The cohort of patients who started treatment in the community of Castilla-La Mancha between 2010 and 2012 and remained on hemodialysis treatment was analysed until the end of 2017.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates how changes in protein levels in urine (proteinuria) over time relate to kidney health in patients with complement component 3 (C3) glomerulopathy.
  • Conducted across 35 nephrology departments in Spain, the research analyzed patient data from 1995 to 2020, focusing on the link between proteinuria trends and kidney failure risk.
  • Findings reveal that higher proteinuria levels significantly increase the risk of kidney failure, while a reduction of 50% or more in proteinuria is associated with a decreased risk, highlighting proteinuria changes as useful indicators for predicting kidney outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates C3 glomerulopathy, a kidney disease linked to abnormalities in the complement system, to identify factors influencing treatment outcomes with corticosteroids and mycophenolate mofetil (MMF).
  • - Conducted across 35 nephrology departments in Spain, the research analyzed data from 97 patients diagnosed with C3 glomerulopathy or dense deposit disease to evaluate remission rates and kidney survival.
  • - Results showed that treatment with corticosteroids plus MMF led to significantly better outcomes (79% remission; 14% kidney failure) compared to other treatments, especially in patients with autoantibody-mediated forms, while those with genetic variants had only partial remissions.
View Article and Find Full Text PDF

Background: Drug-induced hemolytic-uremic syndrome (HUS) has shown good response to eculizumab (ECU). We present 2 cases of patients with gemcitabine-induced HUS (GEM-HUS), one of whom was treated with ECU and the other with conventional treatment. Patient 1: A 74-year-old male with resected adenocarcinoma of the pancreas started adjuvant treatment with GEM, but after 5 months GEM was discontinued due to acute kidney injury and severe hypertension.

View Article and Find Full Text PDF